Prednisone vs Deflazacort vs Vamorolone: Which for DMD?
At a Glance
Prednisone, deflazacort, and vamorolone can all slow muscle decline in Duchenne muscular dystrophy, but no option is best for every child. The choice depends on motor function, age, side effects, growth and bone concerns, safety planning, and access.
In this answer
4 sections
Prednisone, deflazacort (Emflaza), and vamorolone (Agamree) are effective corticosteroid medications used to slow muscle decline and prolong walking in children with Duchenne muscular dystrophy (DMD) [1][2]. While all three drugs provide vital motor benefits, they come with different side effect profiles—particularly regarding weight gain, bone health, and growth [3][4].
No single option is universally best for every child. Choosing the right medication is a shared decision based on your child’s age, current function, side effect tolerability, and insurance coverage.
Slowing Muscle Decline
All three medications help delay the progression of muscle weakness, but definitive, long-term evidence comparing all three directly is limited [1][2].
- Prednisone and Deflazacort: In a rigorous 3-year head-to-head clinical trial (the FOR-DMD study), daily prednisone and daily deflazacort performed very similarly in preserving motor function [1]. Some long-term observational data suggest deflazacort might delay the loss of walking slightly longer than prednisone, but these results may be influenced by differences in how the studies were conducted, baseline age, or how long patients stayed on the medication [5][6].
- Vamorolone: Approved in 2023 for children aged 2 and older, vamorolone is a newer medication designed to work similarly to traditional steroids but with fewer side effects [7]. Short-term trials (24 to 48 weeks) and extension studies show it improves and maintains motor outcomes compared to a placebo [2][8]. However, because it is newer, we do not yet have the years-long head-to-head data to prove it preserves walking for as long as the older steroids.
Standard Dosing
These medications are prescribed as a daily oral dose based on your child’s weight. Never adjust or switch doses yourself, as your physician must carefully calculate and adjust the regimen as your child grows.
- Prednisone: Typically given at 0.75 mg/kg (milligrams per kilogram of body weight) per day [9]. While standard of care in DMD clinics, it is not FDA-approved specifically for DMD [10].
- Deflazacort: Usually dosed at 0.9 mg/kg per day [11][1]. It is officially FDA-approved for DMD.
- Vamorolone: The standard recommended dose is 6 mg/kg per day [7][2]. In specific circumstances, a lower dose of 2 mg/kg per day may be considered, but these are not interchangeable routine doses [2].
Comparing Side Effects
The most significant differences between these medications emerge when looking at their side effects.
Summary Comparison Table
| Feature | Prednisone | Deflazacort | Vamorolone |
|---|---|---|---|
| Usual Dose | ~0.75 mg/kg/day [9] | 0.9 mg/kg/day [1] | 6 mg/kg/day [2] |
| Evidence Strength | Proven long-term (3-year direct trial) [1] | Proven long-term (3-year direct trial) [1] | Short-term trials vs placebo (up to 48 weeks) [8] |
| Weight Effects | High risk; more weight gain than deflazacort [12] | Lower risk than prednisone [12] | Risk present; indirect studies show BMI increases [3] |
| Growth | Reduces growth velocity [2] | Reduces growth velocity [13] | Growth-sparing (protects velocity) [2] |
| Bone/Fractures | High risk of fractures [2] | High risk; highest in some observational data [14] | Improves lab biomarkers; fracture risk remains [2] |
| Cataracts | Can cause cataracts [15] | Higher associated risk than prednisone [15] | Unknown / developing long-term data |
| Behavior | Common (mood swings, irritability) [1] | Common, roughly similar to prednisone [1] | Preliminary data suggests fewer issues [16] |
| Adrenal Risk | Suppresses adrenal function [17] | Suppresses adrenal function [17] | Suppresses adrenal function [18] |
Weight Gain
Weight gain is a common challenge. In head-to-head trials, prednisone caused significantly more weight gain than deflazacort [12][3]. While vamorolone was developed to reduce side effects, it is not weight-neutral. In indirect comparisons across different studies, children taking vamorolone experienced increases in Body Mass Index (BMI) that were sometimes higher than those on standard steroids, though BMI can be difficult to interpret when height is also changing [3][4].
Linear Growth (Height)
Standard steroids (prednisone and deflazacort) frequently reduce growth velocity, leading to a shorter predicted adult height [2][13]. Vamorolone is associated with better growth velocity and appears to be “growth-sparing,” making it a preferable option for families highly concerned about stature [2][3]. Please note that DMD itself, as well as delayed puberty, can also affect a child’s natural growth.
Bone Health and Fractures
Fragile bones are a major concern in DMD. While vamorolone appears gentler on certain laboratory bone-turnover biomarkers than prednisone [2], improved biomarkers do not guarantee fewer fractures. Deflazacort has been associated with high fracture rates in some observational studies, though it is unclear if this is due to the drug itself or because patients tend to take it for a longer duration [14].
Important: Vertebral (spine) fractures can be “silent” and painless [19]. Regardless of the medication, your child will need routine bone monitoring, including DXA scans and spinal imaging, as well as vitamin D and calcium assessments [20][21]. Sudden back pain, height loss, or an unexplained decline in mobility warrants a prompt medical assessment.
Behavior and Eye Health
Behavioral changes—such as mood swings, irritability, or aggression—are common with both prednisone and deflazacort, occurring at roughly similar rates depending on how they are measured [1]. Preliminary data suggests vamorolone might cause fewer behavioral issues, but this is not yet a guaranteed benefit [16]. Report urgent changes like extreme aggression, severe insomnia, hallucinations, or safety concerns to your doctor immediately.
Additionally, all systemic steroids can cause cataracts, though some studies link deflazacort to a higher risk than prednisone [15]. Annual, routine eye exams are essential for any child taking these medications [22].
Other Routine Steroid Side Effects
Children on any of these medications require monitoring for elevated blood pressure, blood sugar changes, delayed puberty, gastrointestinal symptoms, and an increased risk of infections [23]. Always consult your care team before giving your child live vaccines.
The Adrenal Warning (Crucial Safety Plan)
It is absolutely critical to understand that all three medications suppress the body’s natural ability to make cortisol (a condition called adrenal suppression) [18]. Cortisol is the stress hormone that helps the body survive physical trauma, fever, and severe illness.
- Never Stop Abruptly: You must never stop or independently taper these medications. Doing so can cause a life-threatening adrenal crisis [17]. If a dose is missed, follow your doctor’s exact instructions for making it up.
- Emergency “Stress Dosing”: If your child experiences a severe illness (like high fever), trauma, or requires surgery, they will need higher “stress doses” of steroids to help their body cope [24].
- Vomiting is an Emergency: If your child is repeatedly vomiting and cannot keep their oral steroid pill down, you must go to the emergency room immediately to receive intravenous (IV) or injectable steroids.
- Action Steps: Ask your doctor for a written, medication-specific stress-dose plan. Keep emergency injectable hydrocortisone on hand if prescribed, ensure your child wears a medical alert bracelet, and share this plan clearly with their school and other caregivers.
Common questions in this guide
Which steroid is best for a child with Duchenne muscular dystrophy?
How do prednisone, deflazacort, and vamorolone differ in weight and growth effects?
What are the usual daily doses of these DMD steroids?
Can a child stop prednisone, deflazacort, or vamorolone suddenly?
What should I do if my child cannot keep a DMD steroid down because of vomiting?
What monitoring does a child need while taking a DMD steroid?
Appointments are short. Make every minute count.
Specialist visits move fast. Let us help you prep so your time goes to what matters.
Side effects
How do prednisone, deflazacort, and vamorolone compare for weight gain and growth?
Treatment options
Would vamorolone be an option for my child, and how strong is its long-term evidence?
Safety planning
Can you give me a written stress-dose plan for my child for illness, trauma, or surgery?
Related questions
Show more
Get notified when new evidence is published on Duchenne muscular dystrophy.
We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.
References
References (24)
- 1
Effect of Different Corticosteroid Dosing Regimens on Clinical Outcomes in Boys With Duchenne Muscular Dystrophy: A Randomized Clinical Trial.
Guglieri M, Bushby K, McDermott MP, et al.
JAMA 2022; (327(15)):1456-1468 doi:10.1001/jama.2022.4315.
PMID: 35381069 - 2
Efficacy and Safety of Vamorolone vs Placebo and Prednisone Among Boys With Duchenne Muscular Dystrophy: A Randomized Clinical Trial.
Guglieri M, Clemens PR, Perlman SJ, et al.
JAMA neurology 2022; (79(10)):1005-1014 doi:10.1001/jamaneurol.2022.2480.
PMID: 36036925 - 3
Vamorolone for Duchenne Muscular Dystrophy: A Cross-Trial Efficacy Comparison With Classic Corticosteroids From the FOR-DMD Trial.
Clemens PR, Berglund A, Schiava M, et al.
Neurology 2026; (107(1)):e214756 doi:10.1212/WNL.0000000000214756.
PMID: 42202243 - 4
Comparing Deflazacort and Prednisone in Duchenne Muscular Dystrophy.
Biggar WD, Skalsky A, McDonald CM
Journal of neuromuscular diseases 2022; (9(4)):463-476 doi:10.3233/JND-210776.
PMID: 35723111 - 5
Real-world outcomes of long-term prednisone and deflazacort use in patients with Duchenne muscular dystrophy: experience at a single, large care center.
Marden JR, Freimark J, Yao Z, et al.
Journal of comparative effectiveness research 2020; (9(3)):177-189 doi:10.2217/cer-2019-0170.
PMID: 31922454 - 6
Deflazacort vs prednisone treatment for Duchenne muscular dystrophy: A meta-analysis of disease progression rates in recent multicenter clinical trials.
McDonald CM, Sajeev G, Yao Z, et al.
Muscle & nerve 2020; (61(1)):26-35 doi:10.1002/mus.26736.
PMID: 31599456 - 7
Vamorolone: First Approval.
Keam SJ
Drugs 2024; (84(1)):111-117 doi:10.1007/s40265-023-01986-2.
PMID: 38103149 - 8
Efficacy and Safety of Vamorolone Over 48 Weeks in Boys With Duchenne Muscular Dystrophy: A Randomized Controlled Trial.
Dang UJ, Damsker JM, Guglieri M, et al.
Neurology 2024; (102(5)):e208112 doi:10.1212/WNL.0000000000208112.
PMID: 38335499 - 9
Practice guideline update summary: Corticosteroid treatment of Duchenne muscular dystrophy [RETIRED]: Report of the Guideline Development Subcommittee of the American Academy of Neurology.
Gloss D, Moxley RT, Ashwal S, Oskoui M
Neurology 2016; (86(5)):465-72 doi:10.1212/WNL.0000000000002337.
PMID: 26833937 - 10
Comparison of pharmaceutical properties and biological activities of prednisolone, deflazacort, and vamorolone in DMD disease models.
Liu G, Lipari P, Mollin A, et al.
Human molecular genetics 2024; (33(3)):211-223 doi:10.1093/hmg/ddad173.
PMID: 37819629 - 11
A Review of Deflazacort for Patients With Duchenne Muscular Dystrophy.
Bylo M, Farewell R, Coppenrath VA, Yogaratnam D
The Annals of pharmacotherapy 2020; (54(8)):788-794 doi:10.1177/1060028019900500.
PMID: 32019318 - 12
Efficacy and safety of deflazacort vs prednisone and placebo for Duchenne muscular dystrophy.
Griggs RC, Miller JP, Greenberg CR, et al.
Neurology 2016; (87(20)):2123-2131 doi:10.1212/WNL.0000000000003217.
PMID: 27566742 - 13
Corticosteroid Treatment and Growth Patterns in Ambulatory Males with Duchenne Muscular Dystrophy.
Lamb MM, West NA, Ouyang L, et al.
The Journal of pediatrics 2016; (173()):207-213.e3.
PMID: 27039228 - 14
Fractures and Linear Growth in a Nationwide Cohort of Boys With Duchenne Muscular Dystrophy With and Without Glucocorticoid Treatment: Results From the UK NorthStar Database.
Joseph S, Wang C, Bushby K, et al.
JAMA neurology 2019; (76(6)):701-709 doi:10.1001/jamaneurol.2019.0242.
PMID: 30855644 - 15
Cataract development associated with long-term glucocorticoid therapy in Duchenne muscular dystrophy patients.
Rice ML, Wong B, Horn PS, Yang MB
Journal of AAPOS : the official publication of the American Association for Pediatric Ophthalmology and Strabismus 2018; (22(3)):192-196 doi:10.1016/j.jaapos.2018.01.017.
PMID: 29733899 - 16
Efficacy and safety of vamorolone in Duchenne muscular dystrophy: An 18-month interim analysis of a non-randomized open-label extension study.
Smith EC, Conklin LS, Hoffman EP, et al.
PLoS medicine 2020; (17(9)):e1003222 doi:10.1371/journal.pmed.1003222.
PMID: 32956407 - 17
A structured approach to address variability in the global management of adrenal insufficiency in Duchenne muscular dystrophy: the 2025 PJ Nicholoff steroid protocol.
Sbrocchi AM, Ahmet A, Kinnett K, et al.
Frontiers in neurology 2026; (17()):1926817 doi:10.3389/fneur.2026.1926817.
PMID: 42787106 - 18
Adrenal Suppression From Vamorolone and Prednisone in Duchenne Muscular Dystrophy: Results From the Phase 2b Clinical Trial.
Ahmet A, Tobin R, Dang UJ, et al.
The Journal of clinical endocrinology and metabolism 2025; (110(2)):334-344 doi:10.1210/clinem/dgae521.
PMID: 39097643 - 19
Long-Term Outcome of Interdisciplinary Management of Patients with Duchenne Muscular Dystrophy Receiving Daily Glucocorticoid Treatment.
Wong BL, Rybalsky I, Shellenbarger KC, et al.
The Journal of pediatrics 2017; (182()):296-303.e1 doi:10.1016/j.jpeds.2016.11.078.
PMID: 28043681 - 20
Optimizing Bone Health in Duchenne Muscular Dystrophy.
Buckner JL, Bowden SA, Mahan JD
International journal of endocrinology 2015; (2015()):928385 doi:10.1155/2015/928385.
PMID: 26124831 - 21
Growth, pubertal development, and skeletal health in boys with Duchenne Muscular Dystrophy.
Ward LM, Weber DR
Current opinion in endocrinology, diabetes, and obesity 2019; (26(1)):39-48 doi:10.1097/MED.0000000000000456.
PMID: 30507696 - 22
Managing growth and puberty concerns in individuals with Duchenne muscular dystrophy: Updated guidance and future directions.
Rutter MM, Crane JL, Babalola F, et al.
Journal of neuromuscular diseases 2026; 22143602261486896 doi:10.1177/22143602261486896.
PMID: 42857968 - 23
Observational study of changes to glucocorticosteroid prescribing patterns in duchenne muscular dystrophy in the UK over the last decade.
Landon G, Stimpson G, Guglieri M, et al.
Journal of neurology, neurosurgery, and psychiatry 2025; (96(8)):794-801 doi:10.1136/jnnp-2024-335223.
PMID: 39939137 - 24
Adrenal Suppression in Duchenne Muscular Dystrophy: Management Strategies Incorporating Novel Steroid Vamorolone.
Sbrocchi AM, Kinnett K, Lautatzis ME, et al.
Journal of the Endocrine Society 2026; (10(2)):bvaf181 doi:10.1210/jendso/bvaf181.
PMID: 41509125
This comparison is for informational purposes only and does not constitute medical advice. Do not change, stop, or switch your child's steroid without a clinician's plan, because adrenal suppression can be dangerous.